

NATIONAL PSMA PET-CT REFERRAL

PATIENT DETAILS

Patient name:

DOB:

Phone:

Address:

Medicare:

Clinical trial / ID no.:

EXAMINATION

PET PSMA with Whole Body Diagnostic CT (Head, Chest, Abdo, Pelvis)

Plus Extremity (eg. Melanoma, Sarcoma, Myeloma, PUO, Vasculitis/Arteritis, Rheumatological or where limb involvement suspected)

PET PSMA with localised diagnostic CT (please tick region/s)

Head Neck Chest Abdo Pelvis Extremity

PET PSMA with Non-Diagnostic CT (attenuation correction)

CLINICAL DETAILS

Please insert value for at least one of the following:

PSA (>10 ng/ml):

Gleason score (> or = 7):

ISUP (> or = 2):

Stage (> or = T2b):

Non-Medicare eligible PSMA

Other clinical details:

- Contrast Allergy
 Renal Impairment
 Diabetic

INITIAL STAGING - 61563

- The patient has intermediate to high-risk prostate adenocarcinoma
 The patient has previously been untreated
 The patient is considered suitable for locoregional therapy with curative intent

RESTAGING - 61564

- The patient has intermediate to high-risk prostate adenocarcinoma
 The patient has undergone prior locoregional therapy and is considered suitable for further locoregional therapy

ASSESSMENT OF LUTETIUM THERAPY SUITABILITY – 61528

- The patient has been treated with at least one taxane chemotherapy
 The patient has been treated with at least one androgen receptor signaling inhibitor

REFERRING PRACTITIONER

Name:

Provider number:

Address:

Follow up appointment:

Send copy to:

Signature:

Date:

PSMA		
Initial staging	61563	Whole body prostate specific membrane antigen PET study performed for the initial staging of intermediate to high risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. Applicable once per lifetime.
Restaging	61564	Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who: (a) has undergone prior locoregional therapy; and (b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation This item can be claimed by patients with: <ul style="list-style-type: none"> • a prostate specific antigen (PSA) increase of 2ng/ml above the nadir after radiation therapy; or • failure of PSA levels to fall to undetectable levels; or • rising PSA serum after a radical prostatectomy. Applicable twice per lifetime.
Assesment of lutetium therapy suitability	61528	Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.

Qscan PET-CT locations

QLD

Qscan Annerley

7/310 Ipswich Rd, Annerley 4103
p: 07 3357 0388 **f:** 07 3357 0380

Qscan Mackay

148 Sams Rd, North Mackay 4740
p: 07 4960 4940 **f:** 07 3144 5623

Qscan Maroochydore

Shop 5, 84 Wises Rd,
Maroochydore 4558
p: 07 5220 8300 **f:** 07 5294 1010

Qscan North Lakes

9 McLennan Ct, North Lakes 4509
p: 07 3448 8840 **f:** 07 3880 6118

Qscan Redcliffe

6 Silvyn Street, Redcliffe, QLD 4020
p: 07 3357 0922 **f:** 07 3283 4277

Qscan Southport

Pacific Private Clinic, 123 Nerang St,
Southport 4215
p: 07 5503 3433 **f:** 07 5503 3444

ACT

Qscan University of Canberra

University of Canberra,
Corner Broula &, Allawoona St,
Bruce 2617
p: 02 6126 5080 **f:** 02 8322 4025

NSW

Qscan Westmead

2B Darcy Rd, Westmead 2145
p: 02 4761 4225 **f:** 02 8331 1920

TAS

Qscan Hobart

2 Melville St, Hobart 7000
p: 03 6240 1940 **f:** 03 6231 4985

WA

Qscan Midland

81 Yelverton Dr, Midland 6056
p: 08 6155 5500 **f:** 08 6266 3719

Qscan Rockingham

2 Civic Blvd, Rockingham 6168
p: 08 9500 8950 **f:** 08 6444 7480



BOOK AN APPOINTMENT

All images are digitally archived for ten years and can be accessed by your doctor online anytime.

Your doctor has recommended you attend Qscan Radiology Clinics. You may choose another provider but please discuss this with your doctor first.